Pharmaceutical Materials

Sacubitril calcium salt, a key component of the heart failure medication LCZ696, functions as a potent neprilysin (NEP) inhibitor. Its mechanism involves blocking NEP, an enzyme that degrades natriuretic peptides, thereby enhancing vasodilation, diuresis, and natriuresis. This compound, marketed as part of Entresto®, has demonstrated significant clinical benefits in reducing cardiovascular mortality and hospitalization rates in heart failure patients. Structurally, it combines a calcium moiety with sacubitril (AHU-377), a prodrug metabolized into the active NEP inhibitor LBQ657. Sacubitril calcium salt’s efficacy stems from its targeted inhibition of NEP, making it a cornerstone in modern heart failure therapy.

Usage： Used as pharmaceutical intermediate.

Packaging and Shipping： 25kg/ drum or as per buyer requirement.

Storage: Ventilated and dry; separate from alkalis, oxidisers, organic materials and flammable materials.

Name	AHU-377 hemicalcium salt
Synonyms	(alphar AHU-377 hemicalcium salt AHU-377 (heMicalciuM salt) LCZ696(valsartan + sacubitril) impurity 1 Ethyl (αR,γS)-γ-[(3-carboxy-1-oxopropyl)amino]-α-methyl-[1,1′-biphenyl]-4-pentanoate hemicalcium salt Calciumbis(4-{[(1S,3R)-1-([1,1′-biphenyl]-4-ylmethyl)-4-ethoxy-3-methyl-4-oxobutyl] amino} -4-oxobutanoate)
CAS	1369773-39-6

Molecular Formula	C48H56CaN2O10
Molar Mass	861.04364
Melting Point	>140°C (dec.)
Solubility	DMSO (Slightly, Heated), Methanol (Slightly)
Appearance	powder
Color	white to beige
Storage Condition	-20°C
In vitro study	Sacubitril (AHU-377) is a single molecule that is comprised of molecular moieties of valsartan, an ARB, and Sacubitril hemicalcium salt, a neprilysin inhibitor (1:1 ratio). Sacubitril (AHU-377) is converted by enzymatic cleavage of the ethyl ester into the active neprilysin inhibiting metabolite LBQ657. The inactive NEPi precursor, Sacubitril hemicalcium salt, does not inhibit collagen accumulation in fibroblasts nor cardiac myocyte hypertrophy. In cardiac fibroblasts, the active NEPi LBQ657 had no discernible effects. In contrast, LBQ657 modestly inhibits cardiac myocyte hypertrophy.
In vivo study	In humans, Sacubitril (AHU-377)(t max 0.5-1.1 h) are absorbed quickly. Sacubitril hemicalcium salt is converted rapidly into LBQ657 with its t max being reached in 1.9-3.5 h. Mean t 1/2 values for the biologically active LBQ657 is 9.9-11.1 h.In vehicle-treated dogs, ANF increases urinary sodium excretion from 17.3±3.6 to 199.5±18.4 pequivkglmin. This effect is potentiated significantly in animals which receive Sacubitril (AHU-377). Urinary volume is also potentiated in animals which receive an iv administration of Sacubitril (AHU-377).

Disclaimer: The above content is for reference and communication only among industry insiders, and does not guarantee its accuracy or completeness. According to relevant laws and regulations and the regulations of this website, units or individuals who purchase related items should obtain valid qualifications and qualification conditions.

If you're ready to take the next step, Leave your message below and we’ll reply soon. 20+ years of chemical manufacturing & export experience, a partner you can trust.